August 2023 tender notification
Te Pātaka Whaioranga - Pharmac is pleased to provide the latest tender results
Download the tender notification [PDF 56 KB]
Tender results
Pharmac has resolved to award tenders for Principal Supply Status for some products included in the 2022/23 Invitation to Tender, dated 31 October 2022.
Some of the pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with Pharmac. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. Pharmac will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to Pharmac, the Pharmacy Guild and the NZULM by:
- For new listings, by 4pm on 12 September 2023 or the 5th of the month prior to listing, whichever is earlier
- For price changes, by 4pm on the 12th of the month prior to the date of subsidy change
Pharmac cannot list a product (and pharmacies cannot claim) without this information.
More information about this process and NOPC forms can be found on our website.
Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link).
Pharmacodes and CTPP codes must be provided to Pharmac by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest).
Pharmac cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
2022/23 Tender – Principal Supply Status applies until 30 June 2026
Community Pharmaceutical tenders – Section B of the Pharmaceutical Schedule
The decisions were as follows:
1. Tenders awarded to pharmaceuticals where at least one other brand is listed.
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
Listing date |
Principal Supply date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|
|
Goserelin |
Implant 3.6 mg, syringe; 1 implant pack |
$65.68 |
$66.48 |
Zoladex (AstraZeneca) |
1 November 2023 |
1 April 2024 |
Teva (Teva) |
|
Goserelin |
Implant 10.8 mg, syringe; 1 implant pack |
$122.37 |
$138.23 |
Zoladex (AstraZeneca) |
1 November 2023 |
1 April 2024 |
Teva (Teva) |
|
Paraffin |
White soft; 2,500 g tub |
$19.99 |
$19.00 |
EVARA White Soft Paraffin (Evara) |
1 January 2024 |
1 June 2024 |
healthE (Jaychem) |
|
Paraffin |
White soft; 450 g pot |
$4.99 |
$4.74 |
EVARA White Soft Paraffin (Evara) |
1 January 2024 |
1 June 2024 |
healthE (Jaychem) |
Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule
2. Tenders awarded to Pharmaceuticals where no other brand is listed
|
Chemical name |
Presentation; |
Pack price |
Principal Supply brand |
DV limit |
Listing date |
Principal Supply date |
|---|---|---|---|---|---|---|
|
Thiotepa1 |
Inj 15 mg vial; 1 vial pack |
$398.00 |
Tepadina (Link)2 |
5% |
1 November 2023 |
1 April 2024 |
|
Thiotepa1 |
Inj 100 mg vial; 1 vial pack |
$1,800.00 |
Tepadina (Link) 2 |
5% |
1 November 2023 |
1 April 2024 |
|
1The price and subidy of Thiotepa (PCT only – Specialist) in Section B of the Pharmaceutical Schedule will also be amended to the above prices from 1 November 2023. 2The Section 29 (s29) restriction from Link’s brand of thiotepa inj 15 mg vial (Pharmacode 2487985) and inj 100 mg vial will be removed from 1 October 2023. |
||||||
3. Tenders awarded to pharmaceuticals where at least one other brand is listed.
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
DV limit |
Listing date |
Principal Supply date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|---|
|
Cefuroxime |
Inj 750 mg vial; 10 vial pack |
$8.59 |
$8.16 |
Cefuroxime Devatis (Devatis) |
5% |
1 December 2023 |
1 May 2024 |
Cefuroxime-AFT (AFT) |
|
Cefuroxime |
Inj 1.5 g vial; 10 vial pack |
$13.69 |
$13.01 |
Cefuroxime Devatis (Devatis) |
5% |
1 December 2023 |
1 May 2024 |
Cefuroxime-AFT (AFT) |
|
Gemcitabine hydrochloride3 |
Inj 43.3 mg per ml (equivalent to 38 mg per ml gemcitabine), 26.3 ml vial; 1 vial pack |
$15.89 |
$18.94 |
DBL Gemcitabine (Pfizer) |
5% |
1 January 2024 |
1 June 2024 |
Gemcitabine Ebewe (Novartis) |
|
Goserelin |
Implant 3.6 mg, syringe; 1 implant pack |
$65.68 |
$66.48 |
Zoladex (AstraZeneca) |
5% |
1 November 2023 |
1 April 2024 |
Teva (Teva) |
|
Goserelin |
Implant 10.8 mg, syringe; 1 implant pack |
$122.37 |
$138.23 |
Zoladex (AstraZeneca) |
5% |
1 November 2023 |
1 April 2024 |
Teva (Teva) |
|
Paraffin4 |
White soft,; 450 g pot |
$4.99 |
$4.74 |
EVARA White Soft Paraffin (Evara) |
5% |
1 January 2024 |
1 June 2024 |
healthE (Jaychem) |
|
3The price and subidy of Gemcitabine hydrochloride (PCT only – Specialist) in Section B of the Pharmaceutical Schedule will also be amended to the above prices from 1 January 2024. The subsidy of gemcitabine inj 1 mg for ECP (Baxter) will not change as a result of this decision. 4Please note the DV limit applies to the pack sizes of 500 g or less and greater than 30 g. |
||||||||
For products included in the 2021/22 and 2022/2023 Invitation to Tender where no announcement has yet been made, either a decision is still pending subject to Pharmac Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification, please contact Pharmac on 0800 66 00 50.